预约演示
更新于：2025-08-20
Netupitant/Palonosetron Hydrochloride
奈妥匹坦帕洛诺司琼
更新于：2025-08-20
概要
基本信息
药物类型 小分子化药 |
别名 Akynzeo、FOSNETUPITANT CHLORIDE HYDROCHLORIDE/PALONOSETRON HYDROCHLORIDE、Fosnetupitant/palonosetron + [9] |
作用方式 拮抗剂 |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂)、NK1R 拮抗剂(神经激肽-1-受体 拮抗剂) |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2014-10-10), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H25ClN2O |
InChIKeyOLDRWYVIKMSFFB-SSPJITILSA-N |
CAS号135729-62-3 |
查看全部结构式(2)
关联
46
项与 奈妥匹坦帕洛诺司琼 相关的临床试验NCT06904235
A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)
ChiCTR2500101568
NEPA and dexamethasone for preventing of chemotherapy induced nausea and vomiting in colorectal cancer patients with high risk factors receiving moderately emetogenic chemotherapy, a single-center experience
ChiCTR2400093323
Study on gastrointestinal adverse reactions associated with myelopathic chemotherapy treated by Netopitam-palonosetron combined with fennel kosher salt acupoint hot compress
100 项与 奈妥匹坦帕洛诺司琼 相关的临床结果
登录后查看更多信息
100 项与 奈妥匹坦帕洛诺司琼 相关的转化医学
登录后查看更多信息
100 项与 奈妥匹坦帕洛诺司琼 相关的专利（医药）
登录后查看更多信息
127
项与 奈妥匹坦帕洛诺司琼 相关的文献（医药）2025-08-09Future Oncology
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.
Review
作者: Tyler, Timothy ; Bonizzoni, Erminio ; Rugo, Hope S ; Inui, Naoki ; Park, Yeon Hee ; Navari, Rudolph M ; Roeland, Eric J ; Iihara, Hirotoshi
AIM:
Because no conclusive data demonstrate superiority among NK1 receptor antagonists (RA), existing antiemetic guidelines regard them as interchangeable. This individual patient data (IPD) meta-analysis compared the efficacy of NEPA (netupitant/fosnetupitant) and aprepitant/fosaprepitant-based regimens in preventing chemotherapy-induced nausea and vomiting (CINV).
MATERIALS & METHODS:
Head-to-head comparative studies published between 2003 and 2022 that evaluated antiemetic prophylaxis of aprepitant or fosaprepitant versus oral or intravenous (IV) NEPA in patients with various cancers receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) were identified through a literature search. We combined individual patient data to assess complete response (no emesis/no rescue medication) and no significant nausea using a two-stage approach.
RESULTS:
A total of six studies involving 2,767 patients were included evaluating NEPA plus dexamethasone versus aprepitant/fosaprepitant plus any 5-HT3RA plus dexamethasone for patients with cancer receiving HEC/MEC. Complete response and no significant nausea rates were similar during the acute (0-24 h) phase but NEPA showed significantly higher rates than aprepitant during the delayed ( > 24-120 h) and overall (0-120 h) phases and on Days 3-5 following chemotherapy.
CONCLUSION:
Improved CINV prevention was observed with NEPA-based regimens, particularly during Days 3-5, highlighting its potential for managing prolonged nausea and vomiting associated with emerging anticancer targeted therapies.
2025-07-11MEDICINE
Efficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy and usefulness of adding olanzapine for grade 2 or higher emesis
Article
作者: Kim, Jae-Joon ; Oh, Sang-Bo ; Na, Jaemin ; Park, Kwonoh
NEPA has demonstrated superiority in preventing chemotherapy-induced nausea and vomiting (CINV) compared to palonestron and non-inferiority compared to aprepitant/granisetron. However, despite the application of NEPA in previous studies, grade (Gr) 2 or higher CINV was reported in 20% to 30% of cases. The aim of this study was to investigate the efficacy of NEPA for CINV prevention in Korean cancer patients treated with highly emetogenic chemotherapy (HEC), and to evaluate the usefulness of adding olanzapine in cases experiencing Gr 2 or higher CINV in previous cycles. A retrospective cohort study was conducted on cancer patients treated with HEC and CINV prophylaxis using NEPA. If Gr 2 or higher CINV occurred, olanzapine 5 mg/day was administered for 5 days. The primary endpoint was the incidence of Gr 2 or higher CINV during cycle 1. Secondary endpoints included the efficacy of olanzapine addition and the identification of risk factors for Gr 2 or higher CINV. 142 patients were analyzed. The median age was 66.0 years, and males were 54.2%. Tumor sites included biliary tract (44%), genitourinary (27%), and breast (9%). HEC regimens included cisplatin < 50 mg/m2 (49%), cisplatin ≥ 50 mg/m2 (20%), carboplatin (18%), and doxorubicin (12%). The incidence of Gr 2 or higher CINV was 23% (33/142), and the incidence of all-grade CINV was 58% (82/142). Among those with Gr 2 or higher CINV, 82% (27/33) were treated with olanzapine combination without dose modification of HEC, and 74% (20/27) improved to Gr 1 CINV. This study showed that NEPA was comparably effective in Korean patients treated with HEC and demonstrated the efficacy of olanzapine combination therapy. Further studies are needed to confirm CINV prophylaxis strategies, either through initial combination with olanzapine in high-risk CINV patients or by adding olanzapine in patients with prior Gr2 or higher CINV.
2025-07-01Translational Cancer Research
The safety and efficacy of NEPA in preventing postoperative nausea and vomiting after general anesthesia during gastrointestinal cancer surgery: a single-center retrospective study
Article
作者: Li, Huikai ; Xu, Linze ; Li, Chao ; Zhang, Yinchao ; Zhang, Jin ; Bai, Yu ; Wu, Dandan
Background:
Postoperative nausea and vomiting (PONV) are common complications after gastrointestinal (GI) tumor surgery under general anesthesia that hinder recovery. This retrospective study, conducted from May to September 2023 at Tianjin Cancer Hospital Airport Hospital, aimed to evaluate the safety and efficacy of netupitant and palonosetron (NEPA) in reducing PONV in such patients.
Methods:
All patients received one NEPA capsule orally the evening before surgery. PONV symptoms, including nausea, vomiting, pain, abdominal discomfort, and satiety, were monitored for 72 hours postoperatively via daily visual analog scale (VAS) score assessment.
Results:
We initially included 50 patients; 45 patients (32 males, 13 females) met the inclusion criteria, with an average body mass index (BMI) of 23.2±4.2 kg/m2 and a mean weight of 66.2±13.2 kg. Within the first 24 hours post-surgery, 6 (14%) patients experienced vomiting, with 20% of these patients having a VAS score above 4; this proportion was 13% within 24-48 hours and decreased to only 4% within 48-72 hours. No vomiting was documented in the 48-72-hour postoperative period, and the incidence of vomiting in patients treated with NEPA was significantly lower than the guideline incidence.
Conclusions:
NEPA demonstrated high efficacy and convenience, with vomiting occurring in only 15% of patients and nausea in 40% within 72 hours after surgery and more patients showed a trend toward a favorable response over time. NEPA has proven to be a safe, effective, and convenient option for preventing PONV in GI cancer surgeries.
100 项与 奈妥匹坦帕洛诺司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 恶心 | 加拿大 | 2017-11-20 | |
| 呕吐 | 加拿大 | 2017-11-20 | |
| 化疗引起的恶心和呕吐 | 美国 | 2014-10-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 乳腺癌 | 临床3期 | 美国 | 2018-03-16 | |
| 乳腺癌 | 临床3期 | 格鲁吉亚 | 2018-03-16 | |
| 脑癌 | 临床2期 | 希腊 | 2025-07-07 | |
| 脑癌 | 临床2期 | 波兰 | 2025-07-07 | |
| 脑癌 | 临床2期 | 罗马尼亚 | 2025-07-07 | |
| 脑癌 | 临床2期 | 土耳其 | 2025-07-07 | |
| 肾母细胞瘤 | 临床2期 | 希腊 | 2025-07-07 | |
| 肾母细胞瘤 | 临床2期 | 波兰 | 2025-07-07 | |
| 肾母细胞瘤 | 临床2期 | 罗马尼亚 | 2025-07-07 | |
| 肾母细胞瘤 | 临床2期 | 土耳其 | 2025-07-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 312 | Oral NEPA | 繭壓糧壓觸觸鏇餘窪範(願鹽範網膚簾範簾鏇糧) = 願餘鹹顧艱窪範艱壓窪 糧顧築鹹遞願構鹽觸鏇 (鹽遞衊襯願艱獵鏇窪淵 ) 更多 | 积极 | 2025-05-30 | ||
繭壓糧壓觸觸鏇餘窪範(願鹽範網膚簾範簾鏇糧) = 衊願窪網製積積鏇廠積 糧顧築鹹遞願構鹽觸鏇 (鹽遞衊襯願艱獵鏇窪淵 ) 更多 | |||||||
临床3期 | 164 | Dexamethasone 5mg | 壓範襯繭壓鑰遞選選繭(蓋選範壓艱糧繭積簾艱) = 遞遞獵齋齋鑰築網醖廠 構壓構網夢艱鬱齋鑰襯 (窪醖顧蓋壓艱製淵選鬱 ) 更多 | 积极 | 2025-05-30 | ||
壓範襯繭壓鑰遞選選繭(蓋選範壓艱糧繭積簾艱) = 糧襯衊範積獵顧窪願淵 構壓構網夢艱鬱齋鑰襯 (窪醖顧蓋壓艱製淵選鬱 ) 更多 | |||||||
N/A | 164 | 醖繭簾壓網夢顧憲廠廠(襯襯壓鏇鑰衊積齋淵積) = 築廠願窪蓋鹹遞襯廠鏇 壓壓繭憲鏇選獵醖積糧 (網襯繭糧網衊衊廠餘齋 ) 更多 | 积极 | 2024-12-07 | |||
N/A | - | - | NEPA 300mg on day 1,5 | 鹽艱齋簾繭膚窪鹽夢觸(膚窪獵願膚鏇夢壓鑰鹽) = 糧簾構窪齋願願艱衊範 製簾艱糧鬱鏇憲艱壓醖 (餘鏇鹽製齋鏇網選鏇鑰 ) 更多 | 积极 | 2024-12-07 | |
NEPA 300mg on day 1 | 鹽艱齋簾繭膚窪鹽夢觸(膚窪獵願膚鏇夢壓鑰鹽) = 網膚蓋襯憲觸廠鑰糧鏇 製簾艱糧鬱鏇憲艱壓醖 (餘鏇鹽製齋鏇網選鏇鑰 ) 更多 | ||||||
临床4期 | 178 | (HEC) | 膚夢鬱遞鹽積網壓艱鬱(艱遞積壓積網顧遞鏇餘) = 製窪夢餘鏇醖齋積積蓋 簾醖淵繭膚顧製鏇鑰蓋 (構鹹夢獵鏇築鬱壓製淵 ) 更多 | 积极 | 2024-05-24 | ||
(MEC) | 膚夢鬱遞鹽積網壓艱鬱(艱遞積壓積網顧遞鏇餘) = 醖壓窪網憲構壓窪鏇衊 簾醖淵繭膚顧製鏇鑰蓋 (構鹹夢獵鏇築鬱壓製淵 ) 更多 | ||||||
N/A | 76 | 糧壓遞壓網糧醖醖築構(選淵襯遞簾淵鹹膚壓築) = 繭夢膚淵選製鹹壓廠襯 觸願觸積窪鏇膚範構窪 (憲艱簾築顧齋網蓋鹽醖 ) 更多 | - | 2023-06-08 | |||
糧壓遞壓網糧醖醖築構(選淵襯遞簾淵鹹膚壓築) = 顧製衊觸鬱鏇衊夢餘獵 觸願觸積窪鏇膚範構窪 (憲艱簾築顧齋網蓋鹽醖 ) 更多 | |||||||
临床3期 | 228 | NEPA plus no further DEX | 膚網夢簾構顧選鹹糧鹹(醖遞網淵繭築鹹簾齋齋) = 遞積齋齋鹽鹹獵鏇醖鑰 範膚構齋糧鬱選廠築夢 (廠觸網鬱餘糧窪鬱齋廠, 59.7 ~ 86.8) 更多 | 积极 | 2023-06-06 | ||
NEPA plus oral low-dose DEX (4 mg) on days 2-3 | 膚網夢簾構顧選鹹糧鹹(醖遞網淵繭築鹹簾齋齋) = 淵顧夢齋窪繭襯願膚顧 範膚構齋糧鬱選廠築夢 (廠觸網鬱餘糧窪鬱齋廠, 62.5 ~ 92.6) 更多 | ||||||
临床4期 | 354 | NEPA (NEtupitant 300mg and PAlonosetron 0.50 mg) | 壓餘憲網製壓廠鬱淵築(壓構選網憲醖繭鬱築壓) = Adverse events were reported in 10 (3.4%) patients, with leg pain being the most common 3(0.8%) 簾糧觸鑰窪積鹽壓壓顧 (鑰醖廠壓餘鹽製衊窪遞 ) | 积极 | 2023-05-31 | ||
N/A | - | 70 | 繭鏇網鬱醖獵構艱齋餘(繭糧鏇糧選襯壓築遞齋) = one patient experienced grade 1 abdominal pain 憲鬱鬱鬱壓顧積鏇鹹糧 (蓋糧醖積壓夢遞醖蓋網 ) 更多 | - | 2023-04-23 | ||
ASCO2022 人工标引  | N/A | 289 | (HEC regimens) | 壓簾廠顧觸糧獵糧觸觸(醖範築窪鬱簾廠繭鏇糧) = 積窪構窪願簾構網繭鏇 窪憲構願選築衊範蓋廠 (鑰糧艱餘選鬱獵鏇壓齋 ) 更多 | 积极 | 2022-06-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用